RNAi & Antisense— Companies & Signals
RNAi and antisense therapies leverage nucleic acid mechanisms to precisely silence disease-causing genes, offering a novel approach to treating a wide range of conditions with potentially greater specificity and fewer side effects than traditional drugs. This innovative modality represents a significant growth area in biotechnology, driven by advancements in delivery technologies and a robust pipeline targeting unmet medical needs. 29 public companies above the $50M floor. Last 90 days: 21 red 8-Ks, 0 insider cluster-buys, 2 running hot in the press.
29
Companies
21
Red 8-Ks · 90d
0
Insider clusters
2
🔥 Media-hot
Companies in RNAi & Antisense
Refine in search →| # | Ticker | Company | Sector | Mkt cap | 1D | 5D | Volume | Heat | Signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | WVE | Wave Life Sciences Ltd. | Healthcare | $1.1B | -2.6% | -7.9% | 2.7M | — | |
| 2 | CDXS | CODEXIS, INC. | Materials | $218.2M | -2.5% | -1.7% | 757K | — | red 8-K |
| 3 | BNTC | Benitec Biopharma Inc. | Healthcare | $384.1M | +2.7% | +3.3% | 98K | — | red 8-K |
| 4 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | Healthcare | $10.5B | +2.0% | -1.8% | 1.7M | — | red 8-K |
| 5 | PRQR | ProQR Therapeutics N.V. | Healthcare | $151.7M | +19.6% | -2.7% | 2.6M | — | |
| 6 | IONS | IONIS PHARMACEUTICALS INC | Healthcare | $12.1B | -0.6% | +6.3% | 2.8M | — | red 8-K |
| 7 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Healthcare | $37.8B | +0.7% | +2.5% | 1.4M | — | red 8-K |
| 8 | TRDA | Entrada Therapeutics, Inc. | Healthcare | $250.8M | -0.4% | +9.1% | 240K | — | red 8-K |
| 9 | KROS | Keros Therapeutics, Inc. | Healthcare | $200.9M | -0.6% | -0.5% | 353K | — | red 8-K |
| 10 | GERN | GERON CORP | Healthcare | $737.7M | -1.5% | -3.0% | 14.6M | — | red 8-K |
| 11 | ABUS | Arbutus Biopharma Corp | Healthcare | $841.5M | +2.2% | +3.5% | 2.5M | — | red 8-K |
| 12 | CAMP | Camp4 Therapeutics Corp | Healthcare | $217.6M | +5.7% | +5.7% | 157K | — | red 8-K |
| 13 | RPRX | Royalty Pharma plc | Healthcare | $24.3B | +1.5% | +6.6% | 2.5M | ⚡ | |
| 14 | A | AGILENT TECHNOLOGIES, INC. | Healthcare | $36.7B | -2.3% | +5.0% | 2.0M | 🔥 | red 8-K |
| 15 | EDIT | Editas Medicine, Inc. | Healthcare | $383.7M | +12.3% | +14.3% | 3.0M | — | red 8-K |
| 16 | DNLI | Denali Therapeutics Inc. | Healthcare | $3.4B | +1.3% | +7.7% | 2.2M | — | |
| 17 | SRPT | Sarepta Therapeutics, Inc. | Healthcare | $1.6B | +1.0% | -3.6% | 3.8M | — | red 8-K |
| 18 | ARCT | Arcturus Therapeutics Holdings Inc. | Healthcare | $198.1M | -0.9% | -5.7% | 395K | — | red 8-K |
| 19 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Healthcare | $11.1B | +2.9% | +2.8% | 447K | — | red 8-K |
| 20 | RVTY | REVVITY, INC. | Healthcare | $11.1B | -1.6% | +12.3% | 2.0M | 🔥 | |
| 21 | VYGR | Voyager Therapeutics, Inc. | Healthcare | $211.5M | -0.3% | -3.8% | 657K | — | red 8-K |
| 22 | QTRX | Quanterix Corp | Healthcare | $146.0M | +5.1% | +30.1% | 1.8M | — | red 8-K |
| 23 | SRRK | Scholar Rock Holding Corp | Healthcare | $5.3B | +0.4% | +11.7% | 2.1M | — | |
| 24 | ESPR | Esperion Therapeutics, Inc. | Healthcare | $811.7M | -0.6% | -0.3% | 5.7M | — | red 8-K |
| 25 | CRSP | CRISPR Therapeutics AG | Healthcare | $4.9B | +2.6% | +3.7% | 1.8M | ⚡ | red 8-K |
| 26 | BBIO | BridgeBio Pharma, Inc. | Healthcare | $13.1B | +2.5% | +4.5% | 3.3M | — | red 8-K |
| 27 | STOK | Stoke Therapeutics, Inc. | Healthcare | $1.9B | +1.2% | +4.6% | 652K | — | red 8-K |
| 28 | CYRX | Cryoport, Inc. | Healthcare | $736.9M | +1.8% | +10.2% | 965K | — | |
| 29 | TWST | Twist Bioscience Corp | Healthcare | $4.7B | -1.5% | +15.5% | 1.7M | — |
Membership is matched by keyword from companies’ SEC business descriptions (10-K Item 1) — deterministic, not AI inference. May not be exhaustive; not investment advice.